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SUMMARY 
A computational approach has been presented for modeling simultaneous diff~~si~~ 
and metabolism in biological membranes. This approach has a virtually m&mile 
flexibility in the variety and complexity of metabolic schemes that can be m 
Furthermore, non-uniform enzyme distributions, as well as composite membran 
any number of layers, can also be handled. Example calculations have been presente 
(using a real system currently being investigated in the author’s laboratory) which show 
that the versatility of this approach is a necessity for the quantitative study of the system. 
Furthermore, the utility of this approach in guiding decisions as to what path to take in 
improving a prodrug for a given system is amply illustrated. It is expected that this 
physical modeling approach, when combined with techniques now being developed for 
determining the values of the various mcdel parameters, will provide a very useful tool in 
the investigation and optimization of drug delivery systems. 
INTRODLJCTJON 
The ability to quantitatively study the simultaneous diffusion and membrane mctabo 
lism of drugs is a prerequisite to rational dosage form design. Unfortunately, analytic 
solutions to the equations used to model these processes are available only for a very few 
simple cases. In this paper, we will present a computational approach that is applicable to 
the more complex cases which arise regularly in real biological systems. 
BACKGROUND 
The development of quantitative predictive models for drug permeations was initial ~1 
by Scheupleir and co-workers (Scheuplein, 1965, 1967; Scheuplein et al., 1969). For the 
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first time the skin barrier was considered in terms of the fractional areas and absolute 
thicknesses of its strata and other parts. Diffusivities and partition coefficients were 
recognized as the irnpo%rtt flux-determining properties of a given compound, and the 
structure dependence of these properties within a simple homolog(~us series (the 
n-aikands) was also noted. 
The concept introduced in the Scheuplein model were used as the basis for a more 
advanced model in which *be effects of pH were also included in studies of the absorption 
of various series of ionizable species by human buccal tissue and rat intestinal tissue 
(Suzuki et al., 1970a, b; Ho and ~Bguchi, 1971; Ho et al., 1972). More recently, models 
have evolved which consider the simultaneous transport and metabolis~n of drugs by 
various biomembranes (Rogers, 1975; Ando et al., 1977; Park, 1977; Ho et al., 1976). 
Yu et al. (1977) has recently presented a simple model for a more complex chemical 
system, namely one in which prodrug is converted to the active drug, which in turn is 
converted to an inactive metabohte. This paper also describes how values for the various 
parameters in the model could be experiment~ly determined. 
The present paper will describe the numerical methods used to solve much more 
general models than any mentioned above. The determination of parameter values for 
these more general models demands a combination of new theoretical techniques, some- 
times coupled with new expe~mental methods, both of which will be described in future 
publications. 
MEMBRANEDIFFUSIONANDMETABOLISM:THEGENERALCASE 
This paper will be restricted to the case where the system under study is assumed to 
be in a steady-state. Even so, the only interesting case where an~ytic~ solutions to the 
system are readily obtainable is when the metabdism obeys first-order kinetics and the 
responsible enzyme is uniformly distributed throughout the membrane. Ando and 
Kirschner (1976) showed that an analytical solution was also obtainable for the case 
where first-order kinetics was obeyed and the enzyme level was directly proportional to 
the p~ition coordinate in the membr~e, but the solution to this restricted case involved 
fractional order Bessel functions and would therefore be non-trivial to evaluate. 
The present approach places no restrictions whatsoever on enzyme activity profiles 
(other than that they be at least piecewise continuous functions). In addition, the kinetic 
rate law describing the metabolism could be simple first-order or could involve Michaehs- 
Menten kinetics or competitive, non-competitive, or unco~llpetitive in~bition, The 
approach can handle composite membranes, where diffusivities and metabolic properties 
differ from layer to layer. Xn addition, systems involving several components can be 
handled as readily as single component systems. 
For purposes of illustration, we will consider a single example system that illustrates 
many of the complexities found in real systems that our approach is capable of handling. 
We will consider a relatively simple model in which the skin is composed of two regions, 
the stratum corneun~ and the dermis. The system will have three che~nic~ components of 
interest, which we will denote as prodrug, drug, and me 
real system in which a relatively non-active compoun 
relatively active compound (drug), which in turn is m 
pound (metabolite). We shall assume that both metaboli; ste 
kinetics, and furthermore that the drug to metabolite step can 
by the prodrug as well as by an inhibitor that cou 
metabolic scheme is m accordance with one currently 
ries for the transport and metabolism of prodrugs of 9. 
(ara-A). Lipper (1978) has shown this scheme to be o 
kinetic studies and in ccl: suspension studies of the 
and a prodrug, ara-A-5’-valerate. 
M~thernatical description of the model 
The model for the example system we shall use in this paper is s, 
convenience the stratum corneum and dermis will be referred to 
regions of the model and their thickness denoted by L and R. ~o~~~~?r~ti 
drug, and metabolite will be denoted by P, D, and M. Diffusivities of ~~~ B 
two regions of the model will be symbolized by DSQ where S repre 
and Q the region. For example, DDR represents the Diffusivity of 
hand region (the dermis). The activities of the enzymes in the dermis res 
prodmg to drug and drug to metabolite conversions will be denoted 
(Recall that these may vary with position coordinate.) In the example c 
assumed that there is no enzyme activity in the stratum corneum. 
The differential equations describing the simultaneous diffusion and al 
dermal region are then developed as follows. The rate of enzymatic convt: 
to drug (assuming Michaelis-Menten kinetics) is given by: 
%lltlXl PI --- 
Km1 + PI 
STRATUN 
CORNELJN DERMIS 
x - -L x=0 X-R 
Fig. 1. Schematic of two layer skin model used in esample calculation. 
and the rate of conversion of drug ,to metabolite is given by : 
k 
where this metabolic step is assumed to be competitively ir>bibited by both prodrug and 
another inhibitor, I, which could be added to the system. (In some of our experiments 
with ara-A, coviderabine has been used in this capacity.) 
The differential equation describing the behavior of prodrug is obtained by combining 
the diffusion equation (Fick’s second law) with the first term above for prodrug metabo- 
lism to give 
vmaxl[pl am _ DPR a2 Pi 
I_- 
at 69 Km1 + PI 
Assuming steady-state (i.e. 3 [P] /a t = 0), and omitting the brackets, this becomes 
DPR f;r 
dx2 - 
‘mid ’ ’ = 0 
K,,tP - 
Similar treatments yield the differential equations for the steady-state behavior oif the 
drug and the metabolite. These equations can then be rewritten as: 
DPR$-1:;; p=O . 
DDR$ 
El - P E2 - D 








El = Vmax~/Kmr 
KPI = l/K,1 
E2 =V mart2lL2 
KD = ML,2 
KP2 = l/K1 




The above forms were chosen for mathematical convenience in that an effect can be 
omitted from the system simply by zeroing the appropriate coefficient. 
45 
Since there are no metabolic processes occurring in the stratum corneum the solutions 
to the diffusion equations result in linear concentration gradients in this region. These 
solutions can be combined with the boundary conditions at x = -L and the stipulation 
that fluxes be continuous to give the following set of boundary conditions for x = 0: 
y (PL - P(0)) = -DPR - P’(0) 
‘+ (DL - D(0)) = -DDR - D’(0) 
‘+ (ML - M(0)) = -DMR * M’(0) 
where 
PL, DL, ML = the given concentrations of prodrug, drug, 
and metabolite at x = -L; 
P(O), D(O), M(0) = the concentrations at x = 0 
P’(O), D’(O), M’(O) = the gradients in the dermis at x = 0 
At x = R, concentrations of the various species are assumed to be zero: 
P(R) = D(R) = M(R) = 0 
(24 
(3) 
Computation solution of the model 
Eqns. 1-3 represent a boundary value problem with mixed boundary conditions at 
the left-hand side and Dirichlet conditions at the right-hand side. In the general case, for 
a system such as this, all the equations must be solved simultaneously. Examination of 
this system, however, reveals that they may be solved in sequence. The prodrug concen- 
tration profile is computed first, for it is independent of the other concentrations; then 
the drug profile, which is dependent only on the prodrug profile; finally the profile for 
the metabolite is computed. 
As the solutions for these equations are obtained in very similar manners, we will 
describe in detail the solution process for the first one only. This equation represents a 
non-linear boundary value problem, and thus will necessitate use of an iterative technique 
in obtaining its solution. Although problems of this type may be solved by using either 
finite difference or finite element techniques, the use of either of these families of tech- 
niques requires considerable developmental time just to ensure that the chosen method is 
both stable and sufficiently accurate for the problem being solved. Furthermore, the 
stability and accuracy characteristics of a chosen scheme might change if the model were 
modified. For these reasons we wanted to use a technique which could incorporate an 
already developed software component (in this case an ordinary differential equation 
solver) capable of controlling the accuracy of the calculation and also of minimizing the 
amount of work necessary to achieve this accuracy. Finally, it was desirable that the 
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technique be such th.at changes in the model could be easily incorporated. 
The method chosen was the method of adjoints, one of a family of techniques known 
as ‘shooting methods’, several of which are mathematically equivalent although formu- 
lated quite differently (Shipman and Roberts, 1972). The general scheme behind the 
various shooting methods is the following: a set of initial values for the problem is chosen 
that is consistent with the boundary conditions for the left-hand side; the system is 
integrated from left to right; if the result of this integration satisfies the right-hand 
boundary condition, the problem is solved; if not, a d,ifferent set of initial conditions is 
chosen and the procedure repeated. The method of adjoints provides a means of choosing 
the initial conditions for repeating the integration. 
Implicit in this scheme is the assumed ability to accurately integrate the nonlinear 
equation(s). We have chosen an integrator written by Gear (1971) which is capable of 
solving ‘stiff systems of oquations, which are systems where greatly differing coefficients 
arising in the equations can effectively prohi%t accurate solution via more general 
numerkal techniques. Unfortunately, this technique requires more information than con- 
ventional techniques. For a system of equations written as 
Y’ = Es(Y) 
stiff methods require the ability to compute the matrix of partial derivatives 
in addition to the ability to compute y’. Even so, this is a small price to pay for the 
assurance that a method is ‘robust’ in the sense that most p?.vsically reasonable problems 
are handled without difficulty. 
The solution of Eqn. 4 by the method of adjoints is as follows. Redefine the equation 




YI =pL .f wheref= 1 t---- 
DPL*R 
dyl 
Y2 = dt 
~YZ d2y, -= R2 - El/DPR * y 1 -=--..-. -.- 
dt dt 1 + KPl ’ PL * y,/f 
or y’ = Uy 
where U = 
0 1 
R2 m El/DPR -- 





The boundary conditions become 
qr = 1 --yr(0)tDPL-R DpR : L (1 + y*(O)) = 0 
q2 3 y&) = 0 
The maltrix of partia!s needed by the integrator is: 
R2 - El/DPR 
KPl * PL * yr/f)s 
(““a) 
This system is integrated from t = 0 to t = 1 with the yt profde being saved. Then 
and q2 are calculated, and if ?ess than some preset tolerance, the problem is considered 
solved. atherwise, it is necessary to integrate the system of adjoint equations: 
, 
x = -UTx (91 
from x = 1 to x = 0 with the initial conditions 
1 
x(l) = 0 0 
where -UT is the negative transpose of U. As U is not a function of x, the matrix of 
partials is also given by -UT. In perfo~~g this ~nte~a~on it is necessary to be able to 
compute El and yr for given vahres of t. For this reason the y 1 proftie was saved as it was 
formed and values of y1 for a given value of t then obtained using a spline interpola;.~n 
technique. 
The new initial values for y are then calculated as fohows. Compute 6y(O) from 
where the first row of the matrix is the first row of aq/ay. Then set 
Y(O) = Y40) + SY(O) 021 
and begin the process again. The method of adjoints is capable of handling any combina- 
tion of Di~c~et, Neum~n, or m&&d bounda~ condjtions. This problem is a s~rnp1~ 
example of the more general problem, which is described elsewhere (Shipman and 
Roberts, 1972). 
The overall organization of the computer program used for calculations inv~~~in 
diffusion metabolism mode1 is shown in Fig. 2. The hierarchy of the va~ous n~rn~~~ 
routines is dictated by the nature of the technique being used. It should be noted, hew 
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Pig. 2. Orgnnizational structure of computer program to solve steady-state prodrug-drug-metaboite 
~m~Itaneous d~f~sion and metallic probiem. 
used only on occasion to set values of parame 
entry points are used as needed by higher level routines. A 
facilitates writing and making changes to the program becuase t 
among routines is greatly minimized. Unfortunately this sc 
of both program dc velopment time and actual pr 
compatible with tne FORTRAN dialects use 
encounter no difficulties when using the IBM leve 
on the other hand, produces code that does not execute 
The main program is written in FLECS (Beyer, 
FORTRAN whicn has several additional mechanisms for c~ntr(~~in 
have found FLECS to be of tremendous val 
muhitude of possible program flow patterns. 
Example calculations and applications to drug de&w 
Some example calculations will be presented ir order to ~ustr~te t 
computationa! approach has for handling quite complex diffusio 
and also to show that this capability is indeed essential for the ~y~t~~~~ 
TABLE 1 




stratum corneum thickness 
Cermal thickness 
PL concentration of prodrug on left-hand side (assumed 
equal to prodrug solubitlity) 
DL, ML concentration of drug and mettbolite on left-hand side 0 
DFL diffusivities of prodrug 
DDL drug and metabolite 
DML in stratum corneum 
DPR diffusivities of prodrug 
DDR drug, and mctabolite 
DMR in dermis 
KPI 1 /Kmt (esterase) 
KD 1 /Km2 (deaminase) 
KP2 l/K1 (desminasc) 
K12 l/Ktnhtb (dcaminasc) 
ElMAX maximum value of V,,, r/K,t (csterasc) 
ElMAX maximum value of Vmexa/Km2 
e-3 r_lWW”.S_ 




El -II) E2 -x 
El Imx - -JmwE-aa E2m- 4.ooME-03 
Fig. 3. Normalized enzyme activity profiles used in example calculation: El, esterase; E2, deaminase. 
Furthermore, the possibility for the direct application of these calculations to rational 
drug design will be illustrated. 
Using reasonable estimates for values of the various parameters (see Table I), the con- 
centration profiles resulting from the steady-state transport and metabolism of ara-A-S’- 
valerate from a saturated aqueous solution into and through the hairless mouse skin were 
calculated. Ara-A-5’.valerate (the inactive prodrug) is de-esterified to form ara-A (thought 
to be an active antiviral), which is in turn deaminated to the inactive ara-hypoxanthine 
(ara-H), this latter step being competitively inhibited by the prodrug. This syst;?m is 
modelled by Eqns. la-c. In examining the results of the calculation, it should be borne 
in mind that the parameter values used were only estimates; for example, the dermal 
enzyme activity profiles shown (normalized) in Fig. 3 were used (since the act.ual profiles 
have not been resolved yet), and the saturability of deaminase by ara-A and its competi- 
tive inhibition by the prodrug were assumed to quantitatively correspond to results 
obtained from beaker experiments’with a commercially available deaminase preparation. 
Nonetheless, the example calculations should provide a good qualitative idea of what 
might later be expected from calculations using more accurately known parameter 
values. 
The calculated normalized dermal concentration profiles of ara-A-5’-valerate, ara-A, 
and ara-H (denoted by P, D, and M, respectively) are shown in Fig. 4. The calculated 
ara-A level at the left-hand side of the dermal region is at about (or slightly above) the 
level thought to be necessary for antiviral activity in vero renal tissue culture (Williams 
and Lerner, 1975). This is indicative of the possibility that the S’valerate ester might be 
ahnost good enough to be an effective antiviral agent in the hairless mouse skin. The fact 
that the concentration profiles for the three species are all at comparable levels means 
that any change in the parameters describing the metabolic processes would directly 
affect the calculated profiles. Also of note is that the calculated level of 5’-valerate is 
such that the ara-A to ara-H rate of conversion is reduced between 50% and 75% through 
CONCENTHRTION PROFILES 
Fig. 4. Normalized concentration profiles in dermis in example calculation: P, prodrug (ara-Ad’- 
valerate); D, drug (ara-A); M, metabolite (ara-H). 
approximately the first half of the dermal region as a result of the competitive inhibition 
of this step by the prodrug. 
The results of the above calculation show the futility of attempting prodrug design 
in this system without the capability of quantitatively accounting for changes in each of 
the relevant parameters. For the system shown in this calculation there are no fewer than 
four parameters that must be considered in assessing the effect of modifying the prodrug 
These parameters are: 
(1) Solubility of the prodrug 
(2) Permeability of the prodrug (especially to the stratum corneum, but also to the 
dermis) 
(3) Metabolism of the prodrug ara-A 
(4) Ability to competitively inhibit the ara-A to ara-H conversion. 
The effects of changing the values of these parameters have been assessed in a series of 
calculations which are .summarized in Figs. S-10. In these calculations we vary each 
parameter separately, while holding the others constant, even though any change in the 
structure of the prodrug is apt to change all of these parameters. We are currently study 
ing the S’-acetate and 5’.octanoate esters of ara-A as well as the 5’.valcrate in order to 
begin to see how the various parameters depend on molecular structure. .4s a measure of 
activity we will use the area under the dermal concentration profile curve. This quantity 
has units of mmol/cm2 and corresponds to the amount of ara-A per unit area of dermis. 
In our calculations we will study the effects of changes in prodrug solubility, rate of 
prodrug conversion to drug, and in ability of the prodrug to inhibit the metabolism of 
drug to metabolite. 
Fig. S shows the effect of prodrug solubility on ara-A activity. The very sli 
tions of the curve from the strict linearity seen at the low end are a result of 




LOGllf (FRODRUG SOLUBILITYl 
Fig. 5. Dependence of ara-A activity on prodrug solubility. Model calculation for intact hairless mouse 




Fig. 6. Dependence of ara-A activity on the ability of prodrug to inhibit deamination of ara-A. Model 





Fig. 7. Dependence of ara-A activity on the lability of prodrug to esterase. Model calculation for intact 
hairless mouse skin. (* indicates ara-A-5’-valerate.) 
middle of the curve and the esterase (responsible for the prodrug to drug c~nve~ion) at 
the top end of the curve. The star in the middle indicates where the S’valerate falls on 
the curve and shows that for this system an increase or decrease in prodrug solubility will 
result in an approximately proportionate change in ara-A activity. 
Fig. 6 shows the depeudence of ara-A activity on the ability of the prodrug to inhibit 
the drug to metabolite conversion. This is an extremely valuable plot for the would be 
designer of an ara-A prodrug. It shows that even if the prodrug were to completely inhibit 
this conversion, ara-A levels would increase only by about two-fold, whereas if there 
were no inhibition whatsoever, the ara-A level would decrease by only about 40%. This is 
somewhat surprising in light of the fact that in cell suspension studies, the prodrug 
in~bition of drug metabolism results in a rn~~fold increase in intercellular drug levels. 
Furthermore, a deaminase inhibitor (covidaribine) increases the intracellular ara-A levels 
by several orders of magnitude in cell suspensions. As Fig. 6 shows, any attempt to extra- 
polate this tremendous enhancement to the intact hairless mouse skin situation will be 
met with disappointment, as only about a two-fold increase will occur. This result under- 
scores both the importance of approp~ate physics modeling to unde~tanding the 
systems we work with and also the dangers of measuring drug activity in some laboratory 
system and attempting to extrapolate this result to another biological system withqut 
appropriate accounting for geometric as well as biochemical differences. 
Fig. ‘7 shows the result of another possible prodrug modification, the enhancement of 
the lab~ity of prodrug to cleavage by esterase. A naive approach would assume that 
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increasing the lability of prodrug would1 give a concomitant increase in drug activity. As 
Fig. 7 shows, this is not the case at all; in fact, increasing the lability vi11 actually cause a 
slight decrease in drug activity. This is a result of two factors: the lability is already 
sufficiently high to keep up with the p,rodrug diffusion through the stratum corneum; as 
lability increases the penetration through the stratum comeum becomes rate limiting and 
the curve flattens out. In addition, prodrug is also serving as an inhibitor of drug metabo- 
lism; thus as lability increases and prodrug is more rapidly removed, the drug is more 
readily metabolized, resulting in an acltual decrease in drug activity. Hence there is an 
optimum prodrug lability in this system, as Fig. 7 shows, the 5’-valerate is positioned 
almost exactly at this optimum. 
The net conclusion of Fig. 5-7 is that any improvements in the prodrug designed to 
enhance ara-A levels in the intact skin of the test animal will be in the area of enhancing 
solubility. Other possible modifications such as increasing proclrug lability to esterase or 
decreasing the rate of drug deamination awe simply not effective in this system. As we 
shall see in Figs. 8-10, however, if the stratum corneum is removed, our strategy for 
prodrug improvement will be quite different. 
The problem of maximizing ara-A levels in the special case where no stratum corneum 
is present is of more than academic interest. For example, ara-A might be applied there- 
peutically either to skin where the straiturn comeum is absent as a result of lesion forma- 
tion or has been removed as part of the treatment or to vaginal membranes where no 
LOG 10 WWbA/CM-SQl 
vs. 
LOG10 (PRODRUG SOLUBILITY) 
Fig. 8. ijependence of ara-A activity on prodcug solubility. Model calculation fur hairless mouse skin 
with stratum corneum removed. (* indicates ara-A-S’-valerate.) 
stratum corneum is present in the first place, We do not wish to imply that vaginal mem- 
branes are quantitatively or even qualitatively similar to dermis as regards the fat of am-A 
and its prodrugs since experiments to assess this have not yet been done. We cite the 
example of the vaginal ~en~brane simply to point out the impo~ance of the case of 
ara-A transport and metabolism in a membrane without a diffusional barrier in front of it. 
Fig. 8 shows the denendesce of ara-A activity on prcdrug solubility when everything 
in the system is the same as the previous examples, except that no stratum corneum is 
present. The first point worthy of not@ is that the ara-A activity is about 25 times higher 
than when the stratum corneum was present. Second (and somewhat surp~sing), increas- 
ing the prodrug solubility will not .improve +be ara-A level, although a decreased prodrug 
solubihty would lead to a decreased ara-A level. This indicates that the prodrug solubihty 
is already sufficiently high and that some other factor is limiting the attainable ara-A 
level. 
Fig. 9 shows the dependence of ara-A activity on the ability of prodrug to i~bit the 
ara-A to ara-H deamination, This factor, which was relatively u~portant in the case 
where stratum comeum was present, now has almost no effect whatsoever. This is 
because the am-A level is now high enough to approach saturation of the deaminase so 
that deamination only removes a small fraction of the ara-A. Therefore, additional inhibi- 




LOG1 0 OYWWCM-SQI 
vs. 
LOG10 IVMRXl/KMLl 
Fig, 9. Dependence of ara-A activity on the ability of prodrug to inhibit dearnitration of arts-A. Model 
calculation for hairless mouse skin with stratum co:ncum removed. (* indicates araA-S’-valerate.) 
Fig, 10. Dependence of ara-A activity OR the lability of prodrug to esterase. Model calculation for 
hairless mouse skin with stratum corneum removed. (* indicates ~a-A-5’.v~er~te-~ 
The dependence of ara-A activity on the rate of the prodrug to ara-A conversion is 
shown in Fig. 10. This dependence is substantially linear and iindicates that an increase 
in prodrug lability to esterase will result in a proportionate increase in ara-A activity in 
the case where stratum corneum is absent. Hence the am-A level in this system is limited 
by esterase lability, wherease when stratum comeum was present, prodrug solubility wa.s 
the limiting factor ‘. 
DISCUSSION 
The foregoing calculations should make apparent the value of detailed physical model- 
ing to the rational design of prodrugs. Three different factors (prodrug solubility, rate of 
prodrug to drug conversion, and ability of prodrug to inhibit the metabolism of the 
drug) were considered and their relative importances were seen to depend on the system 
being studied. In the intact skin model, ara-A activity could ‘be improved significantly 
only by increasing prodrug solubility, whereas in the model with no stratum corneum 
barrier, the ara-A level could be increased only by increasing the susceptibility of prodrug 
ta esterase. In neither of these situations was the deamination of ara-A an important 
factor. In the case of cell suspensions, however, it has teen shown that deamination is 
important and its inhibition can lead to a many-fold increase in intracellular ara-A levels. 
These conclusions are based on the assumption that in each of these systems ara-A and 
its prodrugs undergo the same metabolic processes. The differences in behavior of these 
model systems are therefore primarily a function of the different geometries and the 
permeabilities of species in the various regions of these systems. 
Th’s suggests a new systematic approach to the rational design of prodrugs. Emphasis 
woulci be placed on the quantitative description of the relevant transport and metabolism 
processes in the target tissue. The use of animal or in vitro systems would be directed 
toward the study of transport and metabolism for a family of prodrugs, with the hope 
that the measured dependencies of these parameters on molecular structure would also 
be applicable to the target organism. Thus, finding model enzyme or cell systems capable 
of mimicing the metabolic fate of the prodrug in the target system would be of primary 
consideration, regardless of the effectiveness of the drug in eliciting a pharmacological 
response in the model system. Developed sufficiently, this detailed physical modeling 
approach should lead directly to the selection of the optimal prodrug from a given family 
of prodrugs for delivery to a specified site of action. 
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